

Supplementary materials

Cerium oxide nanoparticles protect against chondrocytes and cartilage explants from oxidative stress via Nrf2/HO-1 pathway in temporomandibular joint osteoarthritis

Liping Xiong¹, Han Bao¹, Size Li¹, Deao Gu¹, Yuyang Li², Qianwen Yin¹, Wen Li², Leiying Miao^{2*}, Chao Liu^{1*}

¹Department of Orthodontics, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, 210008, China.

²Department of Cariology and Endodontics, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing, 210008, China.

Correspondence:


LeiYing Miao, Ph.D, Professor

Email: miaoleiying80@163.com

Chao Liu, Ph.D, Professor

Email: dxliuchao@163.com

Keywords: Cerium oxide nanoparticles; Temporomandibular joint; Osteoarthritis ; Oxidative stress; Nrf2/HO-1 signal pathway; Cartilage explant



FigureS1. XPS spectrum of CNPs.




Figure S2. Effects of different concentrations of CNPs on iNOS, MMP13 and aggrecan expression levels in inflammatory states. * $P < 0.05$. ** $P < 0.01$. *** $P < 0.001$ relative to the control group.




Figure S3. CNPs reduced the IL-1 β -induced oxidative stress in TMJ-OA chondrocytes. (A) Flow cytometry analysis of intracellular ROS levels; (B) Semi-quantitation of intracellular ROS levels detected by flow cytometry. ** $P < 0.01$, *** $P < 0.001$.





Figure S4. (A) Different concentrations of CNPs promote the mRNA expression of Nrf2 and HO-1. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ relative to the control group.



FigureS5.(A)Relative mRNA expression of IL-6,COX2,iNOS; (B) protein expression of IL-6,COX2,iNOS.** $P < 0.01$. *** $P < 0.001$.

Supplementary Table 1. Primer sequences used in this study.

Gene	Identification	Sequence (5'-3')
<i>GAPDH</i>	Sense	TGCCACTCAGAAGACTGTGG
	Antisense	TTCAGCTCTGGGATGACCTT
<i>Nrf2</i>	Sense	GGTTGCCACATTCCCAAATC
	Antisense	CAAGTGACTGAAACGTAGCCG
<i>HO-1</i>	Sense	GAAGAGGAGATAGAGCGAAACA
	Antisense	CAATCTTCTCAGGACCTGACC
<i>SOD</i>	Sense	CCTGTTCTACTGCAGTTAGGAA
	Antisense	CATCCTTAGCCTAGTTACACGT

<i>CAT</i>	Sense	AAAAGCTAACCTGTAAAGCACG
	Antisense	CTGTTAAGTGATTGCTAAGCCC
<i>GPx</i>	Sense	AGTGCGAGGTGAATGGTGAG
	Antisense	TCGATGTCGATGGTGCGAAA
<i>aggrecan</i>	Sense	CCAGAAGGGTCAGGAGAGAAC
	Antisense	AAAGTGTCCAAGGCATCCAC
<i>Coll1a1</i>	Sense	CAAGATGGTGGCCGTTACTAC
	Antisense	TTAGTCCTTACCGCTCTTCCAG
<i>Col2a1</i>	Sense	GGCTCCAGAACATCACCTA
	Antisense	GCCCTCATCTCCACATCATT
<i>MMP13</i>	Sense	ATGTCATAACCATTTCAGAGCC
	Antisense	ATCCCTTGATGCCATTACCAG
<i>ADAMTS4</i>	Sense	CCCGGAATGGTGGAAAGTATT
	Antisense	TATGACAAGTGCGGAGTATG
<i>iNOS</i>	Sense	AGCATCCACGCCAAGAACG
	Antisense	GTCTGGTTGCCTGGGAAAAT
<i>COX2</i>	Sense	GAGCTGTAAGAGTCTACTGACC
	Antisense	ACACAGGAATCTTCACAAATGG
<i>IL-6</i>	Sense	TGCACTGTCAGAAAACAATCTG
	Antisense	CCAGAGCAGATTTTCAATAGGC

Supplementary Table2. Antibodies used in this study.

MARKER (SPECIES) (Primary antibodies)	DILUTION	DISTRIBUTOR/SOURCE (CATALOGUE NUMBER)
GAPDH Rabbit mAb	1:5000	Abcam;ab181602
Nrf2 Rabbit mAb	1:5000	Proteintech;16396-1-AP
HO-1 Rabbit mAb	1:5000	Abcam;ab68477
aggrecan Rabbit mAb	1:1000	Affinity Biosciences; DF7561
COLI Rabbit mAb	1:1000	Proteintech;14695-1-AP
COLII Rabbit mAb	1:1000	Proteintech;28459-1-AP
MMP13 Rabbit mAb	1:1000	Proteintech;18165-1-AP
ADAMTS4 Rabbit mAb	1:1000	Affinity Biosciences;DF6986
iNOS Rabbit mAb	1:5000	Abcam;ab178945
COX2 Rabbit mAb	1:5000	Abcam;ab15191
IL-6 Rabbit mAb	1:1000	Affinity Biosciences;DF6087